Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Cell Chemical Biology

Volumn 24, Issue 9, 2017, Pages 1181-1190

  Cromm, Philipp M ^a   Crews, Craig M ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E3 ligase; hydrophobic tagging; PROTACs; protein degradation

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UBIQUITIN PROTEIN LIGASE; PROTEIN;

DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOLYSIS TARGETING CHIMERA; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECT; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; UBIQUITINATION;

ANIMALS; DRUG DISCOVERY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROTEINS; PROTEOLYSIS; RECEPTORS, ESTROGEN; SMALL MOLECULE LIBRARIES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 85021144702     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.05.024     Document Type: Review

References (118)

1. Adjei, A.A., What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J. Clin. Oncol. 24 (2006), 4054–4055.
2. Bai, L., Zhou, B., Yang, C.Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 77 (2017), 2476–2487.
3. Bargagna-Mohan, P., Baek, S.H., Lee, H., Kim, K., Mohan, R., Use of PROTACS as molecular probes of angiogenesis. Bioorg. Med. Chem. Lett. 15 (2005), 2724–2727.
4. Berndsen, C.E., Wolberger, C., New insights into ubiquitin E3 ligase mechanism. Nat. Struct. Mol. Biol. 21 (2014), 301–307.
5. Bielskiene, K., Bagdoniene, L., Mozuraitiene, J., Kazbariene, B., Janulionis, E., E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas) 51 (2015), 1–9.
6. Bondeson, D.P., Crews, C.M., Targeted protein degradation by small molecules. Annu. Rev. Pharmacol. Toxicol. 57 (2017), 107–123.
7. Bondeson, D.P., Mares, A., Smith, I.E.D., Ko, E., Campos, S., Miah, A.H., Mulholland, K.E., Routly, N., Buckley, D.L., Gustafson, J.L., et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11 (2015), 611–617.
8. Bradbury, R.H., Hales, N.J., Rabow, A.A., Walker, G.E., Acton, D.G., Andrews, D.M., Ballard, P., Brooks, N.A.N., Colclough, N., Girdwood, A., et al. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorg. Med. Chem. Lett. 21 (2011), 5442–5445.
9. Buckley, D.L., Gustafson, J.L., van Molle, I., Roth, A.G., Tae, H.S., Gareiss, P.C., Jorgensen, W.L., Ciulli, A., Crews, C.M., Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1alpha. Angew. Chem. Int. Ed. 51 (2012), 11463–11467.
10. Buckley, D.L., van Molle, I., Gareiss, P.C., Tae, H.S., Michel, J., Noblin, D.J., Jorgensen, W.L., Ciulli, A., Crews, C.M., Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction. J. Am. Chem. Soc. 134 (2012), 4465–4468.
11. Buckley, D.L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J.L., Smith, I.E., Miah, A.H., Harling, J.D., Crews, C.M., HaloPROTACS: use of small molecule PROTACs to induce degradation of halotag fusion proteins. ACS Chem. Biol. 10 (2015), 1831–1837.
12. Budhidarmo, R., Nakatani, Y., Day, C.L., RINGs hold the key to ubiquitin transfer. Trends Biochem. Sci. 37 (2012), 58–65.
13. Chamberlain, P.P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L.G., Ren, Y.J., Wang, M., et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21 (2014), 803–809.
14. Chatterjee, S., Bhattacharya, S., Socinski, M.A., Burns, T.F., HSP90 inhibitors in lung cancer: promise still unfulfilled. Clin. Adv. Hematol. Oncol. 14 (2016), 346–356.
15. Chu, T.T., Gao, N., Li, Q.Q., Chen, P.G., Yang, X.F., Chen, Y.X., Zhao, Y.F., Li, Y.M., Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation. Cell. Chem. Biol. 23 (2016), 453–461.
16. Coffey, R.T., Shi, Y., Long, M.J.C., Marr, M.T. 2nd, Hedstrom, L., Ubiquilin-mediated small molecule inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 291 (2016), 5221–5233.
17. Conde, J., Artzi, N., Are RNAi and miRNA therapeutics truly dead?. Trends Biotechnol. 33 (2015), 141–144.
18. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
19. Craik, D.J., Fairlie, D.P., Liras, S., Price, D., The future of peptide-based drugs. Chem. Biol. Drug Des. 81 (2013), 136–147.
20. Cromm, P.M., Spiegel, J., Grossmann, T.N., Hydrocarbon stapled peptides as modulators of biological function. ACS Chem. Biol. 10 (2015), 1362–1375.
21. Cromm, P.M., Spiegel, J., Grossmann, T.N., Waldmann, H., Direct modulation of small GTPase activity and function. Angew. Chem. Int. Ed. 54 (2015), 13516–13537.
22. Cyrus, K., Wehenkel, M., Choi, E.Y., Lee, H., Swanson, H., Kim, K.B., Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. Chem. Med. Chem. 5 (2010), 979–985.
23. Cyrus, K., Wehenkel, M., Choi, E.Y., Swanson, H., Kim, K.B., Two-headed PROTAC: an effective new tool for targeted protein degradation. Chembiochem 11 (2010), 1531–1534.
24. Cyrus, K., Wehenkel, M., Choi, E.Y., Han, H.J., Lee, H., Swanson, H., Kim, K.B., Impact of linker length on the activity of PROTACs. Mol. Biosyst. 7 (2011), 359–364.
25. Dauvois, S., Danielian, P.S., White, R., Parker, M.G., Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. USA 89 (1992), 4037–4041.
26. Demizu, Y., Okuhira, K., Motoi, H., Ohno, A., Shoda, T., Fukuhara, K., Okuda, H., Naito, M., Kurihara, M., Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. Bioorg. Med. Chem. Lett. 22 (2012), 1793–1796.
27. Demizu, Y., Shibata, N., Hattori, T., Ohoka, N., Motoi, H., Misawa, T., Shoda, T., Naito, M., Kurihara, M., Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg. Med. Chem. Lett. 26 (2016), 4865–4869.
28. Deng, Y., Wang, C.C., Choy, K.W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T.K.H., Tang, T., Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538 (2014), 217–227.
29. Deshaies, R.J., Joazeiro, C.A.P., RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 78 (2009), 399–434.
30. Erb, M.A., Scott, T.G., Li, B.E., Xie, H., Paulk, J., Seo, H.-S., Souza, A., Roberts, J.M., Dastjerdi, S., Buckley, D.L., et al. Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543 (2017), 270–274.
31. Finley, D., Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78 (2009), 477–513.
32. Fischer, E.S., Bohm, K., Lydeard, J.R., Yang, H., Stadler, M.B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G.M., et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512 (2014), 49–53.
33. Gadd, M.S., Testa, A., Lucas, X., Chan, K.H., Chen, W., Lamont, D.J., Zengerle, M., Ciulli, A., Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13 (2017), 514–521.
34. Galdeano, C., Gadd, M.S., Soares, P., Scaffidi, S., van Molle, I., Birced, I., Hewitt, S., Dias, D.M., Ciulli, A., Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities. J. Med. Chem. 57 (2014), 8657–8663.
35. Grabbe, C., Dikic, I., Functional roles of ubiquitin-like domain (ULD) and ubiquitin-binding domain (UBD) containing proteins. Chem. Rev. 109 (2009), 1481–1494.
36. Gustafson, J.L., Neklesa, T.K., Cox, C.S., Roth, A.G., Buckley, D.L., Tae, H.S., Sundberg, T.B., Stagg, D.B., Hines, J., McDonnell, D.P., et al. Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging. Angew. Chem. Int. Ed. 54 (2015), 9659–9662.
37. Henning, R.K., Varghese, J.O., Das, S., Nag, A., Tang, G., Tang, K., Sutherland, A.M., Heath, J.R., Degradation of Akt using protein-catalyzed capture agents. J. Pept. Sci. 22 (2016), 196–200.
38. Hines, J., Gough, J.D., Corson, T.W., Crews, C.M., Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. Proc. Natl. Acad. Sci. USA 110 (2013), 8942–8947.
39. Hon, W.-C., Wilson, M.I., Harlos, K., Claridge, T.D.W., Schofield, C.J., Pugh, C.W., Maxwell, P.H., Ratcliffe, P.J., Stuart, D.I., Jones, E.Y., Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417 (2002), 975–978.
40. Hong, D.S., Banerji, U., Tavana, B., George, G.C., Aaron, J., Kurzrock, R., Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat. Rev. 39 (2013), 375–387.
41. Hopkins, A.L., Groom, C.R., The druggable genome. Nat. Rev. Drug Discov. 1 (2002), 727–730.
42. Hua, Z., Vierstra, R.D., The Cullin-RING ubiquitin-protein ligases. Annu. Rev. Plant Biol. 62 (2011), 299–334.
43. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., Handa, H., Identification of a primary target of thalidomide teratogenicity. Science 327 (2010), 1345–1350.
44. Itoh, Y., Ishikawa, M., Naito, M., Hashimoto, Y., Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J. Am. Chem. Soc. 132 (2010), 5820–5826.
45. Itoh, Y., Ishikawa, M., Kitaguchi, R., Sato, S., Naito, M., Hashimoto, Y., Development of target protein-selective degradation inducer for protein knockdown. Bioorg. Med. Chem. 19 (2011), 3229–3241.
46. Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., Hashimoto, Y., Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg. Med. Chem. 19 (2011), 6768–6778.
47. Itoh, Y., Ishikawa, M., Kitaguchi, R., Okuhira, K., Naito, M., Hashimoto, Y., Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. Bioorg. Med. Chem. Lett. 22 (2012), 4453–4457.
48. Jego, G., Hazoume, A., Seigneuric, R., Garrido, C., Targeting heat shock proteins in cancer. Cancer Lett. 332 (2013), 275–285.
49. Jin, J., Li, X., Gygi, S.P., Harper, J.W., Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 447 (2007), 1135–1138.
50. Kerscher, O., Felberbaum, R., Hochstrasser, M., Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22 (2006), 159–180.
51. Kirkin, V., Dikic, I., Ubiquitin networks in cancer. Curr. Opin. Genet. Dev. 21 (2011), 21–28.
52. Komander, D., The emerging complexity of protein ubiquitination. Biochem. Soc. Trans. 37 (2009), 937–953.
53. Komander, D., Rape, M., The ubiquitin code. Annu. Rev. Biochem. 81 (2012), 203–229.
54. Kronke, J., Fink, E.C., Hollenbach, P.W., MacBeth, K.J., Hurst, S.N., Udeshi, N.D., Chamberlain, P.P., Mani, D.R., Man, H.W., Gandhi, A.K., et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature 523 (2015), 183–188.
55. Lai, A.C., Crews, C.M., Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16 (2017), 101–114.
56. Lai, A.C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E., Hines, J., Crews, C.M., Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. 55 (2016), 807–810.
57. Lazo, J.S., Sharlow, E.R., Drugging undruggable molecular cancer targets. Annu. Rev. Pharmacol. Toxicol. 56 (2016), 23–40.
58. Lebraud, H., Wright, D.J., Johnson, C.N., Heightman, T.D., Protein degradation by in-cell self-assembly of proteolysis targeting chimeras. ACS Cent. Sci. 2 (2016), 927–934.
59. Lee, H., Puppala, D., Choi, E.Y., Swanson, H., Kim, K.B., Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool. Chembiochem 8 (2007), 2058–2062.
60. Li, W., Bengtson, M.H., Ulbrich, A., Matsuda, A., Reddy, V.A., Orth, A., Chanda, S.K., Batalov, S., Joazeiro, C.A.P., Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One, 3, 2008, e1487.
61. Liang, J., Shang, Y., Estrogen and cancer. Annu. Rev. Physiol. 75 (2013), 225–240.
62. Lim, S.M., Xie, T., Westover, K.D., Ficarro, S.B., Tae, H.S., Gurbani, D., Sim, T., Marto, J.A., Janne, P.A., Crews, C.M., et al. Development of small molecules targeting the pseudokinase Her3. Bioorg. Med. Chem. Lett. 25 (2015), 3382–3389.
63. Lipkowitz, S., Weissman, A.M., RINGs of good and evil: ring finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 11 (2011), 629–643.
64. Loddick, S.A., Ross, S.J., Thomason, A.G., Robinson, D.M., Walker, G.E., Dunkley, T.P.J., Brave, S.R., Broadbent, N., Stratton, N.C., Trueman, D., et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol. Cancer Ther. 12 (2013), 1715–1727.
65. Long, M.J.C., Gollapalli, D.R., Hedstrom, L., Inhibitor mediated protein degradation. Chem. Biol. 19 (2012), 629–637.
66. Lorick, K.L., Jensen, J.P., Fang, S., Ong, A.M., Hatakeyama, S., Weissman, A.M., RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 96 (1999), 11364–11369.
67. Lu, G., Middleton, R.E., Sun, H., Naniong, M., Ott, C.J., Mitsiades, C.S., Wong, K.K., Bradner, J.E., Kaelin, W.G.J.R., The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343 (2014), 305–309.
68. Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J.D., Crew, A.P., Coleman, K., et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22 (2015), 755–763.
69. Metzger, M.B., Hristova, V.A., Weissman, A.M., HECT and RING finger families of E3 ubiquitin ligases at a glance. J. Cell Sci. 125 (2012), 531–537.
70. Metzger, M.B., Pruneda, J.N., Klevit, R.E., Weissman, A.M., RING-type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochim. Biophys. Acta 1843 (2014), 47–60.
71. Min, J.H., Yang, H., Ivan, M., Gertler, F., Kaelin, W.G.J.R., Pavletich, N.P., Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 296 (2002), 1886–1889.
72. Montrose, K., Krissansen, G.W., Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus. Biochem. Biophys. Res. Commun. 453 (2014), 735–740.
73. Neklesa, T.K., Crews, C.M., Chemical biology: greasy tags for protein removal. Nature 487 (2012), 308–309.
74. Neklesa, T.K., Tae, H.S., Schneekloth, A.R., Stulberg, M.J., Corson, T.W., Sundberg, T.B., Raina, K., Holley, S.A., Crews, C.M., Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nat. Chem. Biol. 7 (2011), 538–543.
75. Ohoka, N., Nagai, K., Hattori, T., Okuhira, K., Shibata, N., Cho, N., Naito, M., Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell Death Dis., 5, 2014, e1513.
76. Ohoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. In vivo knockdown of pathogenic proteins via specific and nongenetic IAP-dependent protein erasers (SNIPERs). J. Biol. Chem. 292 (2017), 4556–4570.
77. Okuhira, K., Demizu, Y., Hattori, T., Ohoka, N., Shibata, N., Nishimaki-Mogami, T., Okuda, H., Kurihara, M., Naito, M., Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci. 104 (2013), 1492–1498.
78. Okuhira, K., Shoda, T., Omura, R., Ohoka, N., Hattori, T., Shibata, N., Demizu, Y., Sugihara, R., Ichino, A., Kawahara, H., et al. Targeted degradation of proteins localized in subcellular compartments by hybrid small molecules. Mol. Pharmacol. 91 (2017), 159–166.
79. Orning, L., Krivi, G., Fitzpatrick, F.A., Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J. Biol. Chem. 266 (1991), 1375–1378.
80. Ottis, P., Crews, C.M., Proteolysis-targeting chimeras. Induced protein degradation as a therapeutic strategy. ACS Chem. Biol. 12 (2017), 892–898.
81. Papke, B., Der, C.J., Drugging RAS. Know the enemy. Science 355 (2017), 1158–1163.
82. Pelay-Gimeno, M., Glas, A., Koch, O., Grossmann, T.N., Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes. Angew. Chem. Int. Ed. 54 (2015), 8896–8927.
83. Pelzer, C., Kassner, I., Matentzoglu, K., Singh, R.K., Wollscheid, H.-P., Scheffner, M., Schmidtke, G., Groettrup, M., UBE1L2, a novel E1 enzyme specific for ubiquitin. J. Biol. Chem. 282 (2007), 23010–23014.
84. Petroski, M.D., Deshaies, R.J., Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6 (2005), 9–20.
85. Pickart, C.M., Eddins, M.J., Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695 (2004), 55–72.
86. Puppala, D., Lee, H., Kim, K.B., Swanson, H.I., Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention. Mol. Pharmacol. 73 (2008), 1064–1071.
87. Raina, K., Noblin, D.J., Serebrenik, Y.V., Adams, A., Zhao, C., Crews, C.M., Targeted protein destabilization reveals an estrogen-mediated ER stress response. Nat. Chem. Biol. 10 (2014), 957–962.
88. Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A.M.K., Wang, J., Chen, X., Dong, H., Siu, K., et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 113 (2016), 7124–7129.
89. Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C.M., Deshaies, R.J., Sakamoto, K.M., Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27 (2008), 7201–7211.
90. Saenz, D.T., Fiskus, W., Qian, Y., Manshouri, T., Rajapakshe, K., Raina, K., Coleman, K.G., Crew, A.P., Shen, A., Mill, C.P., et al. Novel BET protein proteolysis targeting chimera (BET-PROTAC) exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Leukemia, 2017, 10.1038/leu.2016.393.
91. Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.M., Deshaies, R.J., PROTACs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98 (2001), 8554–8559.
92. Sakamoto, K.M., Kim, K.B., Verma, R., Ransick, A., Stein, B., Crews, C.M., Deshaies, R.J., Development of PROTACs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell. Proteomics 2 (2003), 1350–1358.
93. Salami, J., Crews, C.M., Waste disposal – an attractive strategy for cancer therapy. Science 355 (2017), 1163–1167.
94. Schneekloth, J.S. Jr., Fonseca, F.N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., Crews, C.M., Chemical genetic control of protein levels: selective in vivo targeted degradation. J. Am. Chem. Soc. 126 (2004), 3748–3754.
95. Schneekloth, A.R., Pucheault, M., Tae, H.S., Crews, C.M., Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18 (2008), 5904–5908.
96. Sekine, K., Takubo, K., Kikuchi, R., Nishimoto, M., Kitagawa, M., Abe, F., Nishikawa, K., Tsuruo, T., Naito, M., Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J. Biol. Chem. 283 (2008), 8961–8968.
97. Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J.H., Gao, Y., Cheng, K.A., Cohoon, T.J., Qi, J., et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 19 (2013), 6183–6192.
98. Spiegel, J., Cromm, P.M., Zimmermann, G., Grossmann, T.N., Waldmann, H., Small-molecule modulation of Ras signaling. Nat. Chem. Biol. 10 (2014), 613–622.
99. Surade, S., Blundell, T.L., Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 19 (2012), 42–50.
100. Taldone, T., Gozman, A., Maharaj, R., Chiosis, G., Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 8 (2008), 370–374.
101. Tomoshige, S., Hashimoto, Y., Ishikawa, M., Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligand. Bioorg. Med. Chem. 24 (2016), 3144–3148.
102. Toure, M., Crews, C.M., Small-molecule PROTACs. New approaches to protein degradation. Angew. Chem. Int. Ed. 55 (2016), 1966–1973.
103. Umezawa, H., Aoyagi, T., Suda, H., Hamada, M., Takeuchi, T., Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J. Antibiot. (Tokyo) 29 (1976), 97–99.
104. Varshavsky, A., Naming a targeting signal. Cell 64 (1991), 13–15.
105. van Molle, I., Thomann, A., Buckley, D.L., So, E.C., Lang, S., Crews, C.M., Ciulli, A., Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1alpha protein-protein interface. Chem. Biol. 19 (2012), 1300–1312.
106. Waldmann, H., Valeur, E., Guéret, S.M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Grossmann, T.N., Plowright, A.T., New modalities for challenging targets in drug discovery. Angew. Chem. Int. Ed., 2017, 10.1002/anie.201611914.
107. Wang, X., Feng, S., Fan, J., Li, X., Wen, Q., Luo, N., New strategy for renal fibrosis: targeting Smad3 proteins for ubiquitination and degradation. Biochem. Pharmacol. 116 (2016), 200–209.
108. Wells, J.A., McClendon, C.L., Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450 (2007), 1001–1009.
109. Whitehead, K.A., Langer, R., Anderson, D.G., Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8 (2009), 129–138.
110. Winter, G.E., Buckley, D.L., Paulk, J., Roberts, J.M., Souza, A., Dhe-Paganon, S., Bradner, J.E., Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348 (2015), 1376–1381.
111. Wittmann, B.M., Sherk, A., McDonnell, D.P., Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 67 (2007), 9549–9560.
112. Wu, Y.-L., Yang, X., Ren, Z., McDonnell, D.P., Norris, J.D., Willson, T.M., Greene, G.L., Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol. Cell 18 (2005), 413–424.
113. Xie, T., Lim, S.M., Westover, K.D., Dodge, M.E., Ercan, D., Ficarro, S.B., Udayakumar, D., Gurbani, D., Tae, H.S., Riddle, S.M., et al. Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10 (2014), 1006–1012.
114. Yarden, Y., Pines, G., The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12 (2012), 553–563.
115. Yau, R., Rape, M., The increasing complexity of the ubiquitin code. Nat. Cell Biol. 18 (2016), 579–586.
116. Zengerle, M., Chan, K.H., Ciulli, A., Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10 (2015), 1770–1777.
117. Zhang, D., Baek, S.H., Ho, A., Kim, K., Degradation of target protein in living cells by small-molecule proteolysis inducer. Bioorg. Med. Chem. Lett. 14 (2004), 645–648.
118. Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.Y., Zhao, Y., et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J. Med. Chem., 2017, 10.1021/acs.jmedchem.6b01816.